⚠ Evidence warning: Clinical trials or other evidence do not support the claim that Korean red ginseng reliably restores erectile function. This page keeps it as a report of what people, websites or other media say.

Ginseng for Erectile Function

Erectile Function — scientific infographic poster

Korean Red Ginseng (KRG) is the best-studied herbal treatment for erectile dysfunction. The Hong 2002 double-blind crossover trial randomized 45 men with clinically diagnosed erectile dysfunction (ED) to KRG 900 mg three times daily (2,700 mg/day total) or placebo for 8 weeks each; the active arm showed significantly higher International Index of Erectile Function (IIEF) scores than placebo (mean 38.1 on ginseng vs 30.9 on placebo, from a baseline of 28.0), with consistent improvements across the rigidity, penetration, and maintenance subscores. The de Andrade 2007 trial in 60 men reported a similar result with a slightly higher dose (1,000 mg three times daily). The mechanism centers on enhanced nitric oxide (NO) synthesis in the corpus cavernosum: ginsenosides Rg1 and Rg3 upregulate endothelial nitric oxide synthase (eNOS), the same enzyme whose downstream messenger cGMP is the target of phosphodiesterase-5 (PDE5) inhibitors like sildenafil and tadalafil. The trials used about 3 g/day of KRG, and practitioners describe effects as detectable by about week 4 and full benefit by about week 8. KRG is not as immediately effective as PDE5 inhibitors; it is proposed to work through a complementary upstream mechanism, and practitioners describe it as an option for men who cannot tolerate or do not respond fully to PDE5 inhibitors, or who prefer a chronic supplement approach to an on-demand drug.


Table of Contents

  1. Erectile Dysfunction Overview — Why Mechanism Matters
  2. The Hong 2002 Korean Red Ginseng Erectile Dysfunction Trial
  3. The de Andrade 2007 Confirmation Trial and Jang 2008 Meta-Analysis
  4. Nitric Oxide Mechanism — How KRG Restores Erectile Function
  5. KRG vs PDE5 Inhibitors (Sildenafil, Tadalafil)
  6. Vascular Endothelial Dysfunction — The Underlying Disease
  7. Standard 3 g/Day Dosing and Timing
  8. Sourcing and Quality — Why KRG Specifically
  9. Additional Sexual Health Effects (Libido, Female Sexual Function, Fertility)
  10. Cautions, Limitations, and Drug Interactions
  11. The 2021 Cochrane Review of Ginseng for Erectile Dysfunction
  12. Key Research Papers
  13. Connections
  14. Featured Videos

Erectile Dysfunction Overview — Why Mechanism Matters

Erectile dysfunction (ED), defined as the persistent inability to attain or maintain an erection adequate for satisfactory sexual performance, affects an estimated 30 million men in the United States and considerably more globally. Prevalence rises with age: ~5% in men under 40, ~15% at age 50, ~30% at age 60, and ~50% or more by age 70. Erectile dysfunction is also strongly associated with cardiovascular disease, diabetes, obesity, smoking, sedentary lifestyle, depression, and certain medications (antihypertensives, antidepressants, antipsychotics, opioids, finasteride).

The proximate physiology of erection involves a parasympathetic nervous system signal triggering nitric oxide (NO) release from the cavernous nerve and from endothelial cells lining the corpus cavernosum. Nitric oxide diffuses into smooth muscle cells of the corpus cavernosum trabeculae, where it activates guanylate cyclase, generating cyclic GMP (cGMP). cGMP relaxes the smooth muscle, allowing blood inflow through the helicine arteries to outpace venous outflow, producing turgid erection. Phosphodiesterase-5 (PDE5) is the enzyme that breaks down cGMP, ending the erection.

The pharmacologic targets in this cascade include:

Ginseng acts at the upstream NO-production layer, which is mechanistically distinct from and complementary to PDE5 inhibition. This makes the combination of KRG plus a PDE5 inhibitor potentially additive (though formal combination trials are limited), and practitioners describe KRG as an option for men in whom PDE5 inhibitors are contraindicated (concurrent nitrate use, severe cardiovascular disease) or who experience PDE5-inhibitor side effects (headache, flushing, visual disturbances, hypotension).

Back to Table of Contents

The Hong 2002 Korean Red Ginseng Erectile Dysfunction Trial

The single most influential clinical trial of an herbal supplement for erectile dysfunction is the Hong 2002 Korean red ginseng trial, published in the Journal of Urology. The trial enrolled 45 men with clinically diagnosed mild-to-moderate erectile dysfunction of at least 6 months' duration and randomized them in a double-blind crossover design to:

The primary outcome was the International Index of Erectile Function (IIEF) score — a validated 15-item questionnaire covering erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. Higher scores indicate better function; the IIEF erectile function domain ranges 0-30, with severe erectile dysfunction below 11 and normal function above 26.

Results:

The Hong 2002 trial was a Phase 2 / Phase 3 quality study by the standards of herbal medicine research. Its main limitations were modest sample size (45 men, with crossover design adding effective statistical power) and single-center conduct. The authors themselves titled it a preliminary report. The findings have been broadly replicated by independent investigators in subsequent years.

An earlier trial points the same way. Choi 1995 followed 90 men in three groups of 30 (ginseng, placebo and the antidepressant trazodone). Overall efficacy was reported as 60% on ginseng and 30% in each of the other two groups (p < 0.05). The authors recorded partial responses only, with no complete remission of erectile dysfunction, and no worsening of symptoms.

Back to Table of Contents

The de Andrade 2007 Confirmation Trial and Jang 2008 Meta-Analysis

The de Andrade 2007 trial enrolled 60 men with erectile dysfunction (mean age 52) and randomized them in a parallel-group double-blind design to KRG 1,000 mg three times daily or placebo for 12 weeks. Results confirmed the Hong 2002 findings: significantly higher IIEF erectile function scores in the KRG arm, with improvements in penetration and maintenance subscores, no excess adverse events. On the five-item version of the questionnaire (IIEF-5), scores went from 16.4 to 21.0 on KRG (P < 0.0001) and from 17.0 to 17.7 on placebo (no significant change), and 20 men on KRG (66.6%) reported improved erections.

In the Jang 2008 systematic review, 7 randomized trials of Korean Red Ginseng for erectile dysfunction met the inclusion criteria, and the 6 that compared it with placebo were pooled (349 men, risk ratio 2.40, 95% confidence interval 1.65 to 3.51). Their methodological quality was low on average. The authors called this "suggestive evidence" and wrote that the number of trials, the total sample size and the quality "were too low to draw definitive conclusions."

What is reported from this body of trials (the dose range, the comparison with PDE5 inhibitors and the safety line are not in the review's abstract):

The later Borrelli 2018 systematic review counted five ginseng trials (399 men) and pooled the IIEF-5 data (standardized mean difference 0.43, 95% confidence interval 0.15 to 0.70). Its authors called this encouraging and wrote that "further, larger, and high-quality studies are required before firm conclusions can be drawn." KRG is often described as one of the few herbal medicines with reproducible randomized-trial support for erectile dysfunction, with a modest effect. KRG is not as immediately effective as PDE5 inhibitors but offers a different mechanism, a chronic-supplement rather than on-demand dosing pattern, and a better tolerated profile in some men.

Back to Table of Contents

Nitric Oxide Mechanism — How KRG Restores Erectile Function

The mechanistic explanation for KRG's erectile benefit centers on enhanced nitric oxide (NO) synthesis in the corpus cavernosum. Ginsenosides Rg1 and Rg3, in particular, act on endothelial nitric oxide synthase (eNOS) and on the L-arginine substrate pool that eNOS uses to generate NO.

Several converging mechanisms have been demonstrated in cell and animal work (the 2002 Murphy and Lee review describes the animal evidence):

The net result is that the same parasympathetic signal that triggers erection produces more robust NO release and more sustained corpus cavernosum smooth muscle relaxation in men taking KRG — without disrupting the physiological off-switch (PDE5-mediated cGMP degradation) that ends the erection appropriately.

Back to Table of Contents

KRG vs PDE5 Inhibitors (Sildenafil, Tadalafil)

The phosphodiesterase-5 (PDE5) inhibitors — sildenafil (1998), vardenafil (2003), tadalafil (2003), and avanafil (2012) — remain the gold-standard pharmacologic treatment for erectile dysfunction. They work by preventing the breakdown of cGMP, allowing the NO signal that initiates erection to produce sustained smooth muscle relaxation.

Comparative considerations for KRG vs PDE5 inhibitors:

How the options are described in practice:

For more on erectile dysfunction itself, see our Erectile Dysfunction page.

Back to Table of Contents

Vascular Endothelial Dysfunction — The Underlying Disease

An important conceptual point about erectile dysfunction is that it is most commonly a manifestation of generalized vascular endothelial dysfunction — the same process that drives coronary artery disease, peripheral arterial disease, and cerebrovascular disease. The penile arteries are smaller than coronary arteries, so endothelial dysfunction shows up there first. Erectile dysfunction in a man without obvious risk factors is now considered an independent predictor of subsequent cardiovascular events within 3-5 years, prompting cardiology evaluation in newly diagnosed erectile dysfunction patients.

This framing changes the therapeutic conversation. Pharmacotherapy (PDE5 inhibitors or KRG) treats the symptom but does not address the underlying endothelial dysfunction. The interventions that address the underlying disease — aerobic exercise (the single most effective intervention for endothelial function), Mediterranean-style diet, weight loss, blood pressure control, glucose control, smoking cessation, sleep apnea treatment — are also the interventions most likely to produce sustained erectile dysfunction improvement and to reduce cardiovascular risk.

Ginseng's NO-supportive mechanism is congruent with this broader endothelial-restoration approach. Several KRG preparations have demonstrated improvements in flow-mediated dilation (a standard measure of vascular endothelial function) in men with cardiovascular risk factors, independent of the erectile dysfunction-specific effects.

For comprehensive cardiovascular management, see our Cardiology page, Hypertension page, and Diabetes page. For exercise as erectile dysfunction therapy, see Exercise.

Back to Table of Contents

Standard 3 g/Day Dosing and Timing

KRG dosing as used in the erectile dysfunction trials and described in practice:

People who get insomnia, sleep disturbance, or anxiety at 3 g/day describe dropping to 2 g/day, and practitioners describe moving to a different treatment if the problem continues at that dose. A small number of men are particularly sensitive to KRG's stimulant effects and tolerate it poorly.

The placebo-controlled trials ran for up to 12 weeks, so what happens beyond that is not known from them. Practitioners treat a lack of full benefit by 12 weeks on 3 g/day as a sign that KRG alone is unlikely to be enough, and describe combining it with a PDE5 inhibitor or changing to a PDE5 inhibitor alone.

Back to Table of Contents

Sourcing and Quality — Why KRG Specifically

"Korean Red Ginseng" specifically refers to Korean-grown Panax ginseng root that has been steamed before drying. The steaming process (typically 90-100°C for 2-3 hours, then sun-drying) converts some of the original ginsenosides to deglycosylated derivatives — particularly Rg3, which is essentially absent in unprocessed white ginseng but present in significant amounts in red ginseng. The steamed root takes on a characteristic reddish-brown color.

Why KRG specifically for erectile dysfunction:

Quality matters greatly. The ginseng marketplace includes some seriously adulterated and underpotent products. Quality indicators people look for:

Back to Table of Contents

Additional Sexual Health Effects (Libido, Female Sexual Function, Fertility)

Beyond the well-documented erectile dysfunction indication, KRG has been studied for several additional sexual health applications:

For related topics, see Hypogonadism, Low Testosterone, and Urology.

Back to Table of Contents

Cautions, Limitations, and Drug Interactions

Back to Table of Contents

The 2021 Cochrane Review of Ginseng for Erectile Dysfunction

The most recent Cochrane review (Lee 2021) searched to January 2021 and included 9 studies with 587 men aged 20 to 70 with mild to moderate erectile dysfunction. Every study compared ginseng with placebo, and follow-up was short, up to 12 weeks.

Back to Table of Contents

Key Research Papers

  1. Hong B et al. (2002). A double-blind crossover study evaluating the efficacy of Korean red ginseng in patients with erectile dysfunction: a preliminary report. Journal of Urology. — PubMed PMID: 12394711
  2. de Andrade E et al. (2007). Study of the efficacy of Korean red ginseng in the treatment of erectile dysfunction. Asian Journal of Andrology. — PubMed PMID: 16855773
  3. Jang DJ et al. (2008). Red ginseng for treating erectile dysfunction: a systematic review. British Journal of Clinical Pharmacology. — PubMed PMID: 18754850
  4. Choi HK et al. (1995). Clinical efficacy of Korean red ginseng for erectile dysfunction. International Journal of Impotence Research. — PubMed PMID: 8750052
  5. Kim TH et al. (2009). Effects of tissue-cultured mountain ginseng (Panax ginseng CA Meyer) extract on male patients with erectile dysfunction. Asian Journal of Andrology. — PubMed PMID: 19234482
  6. Oh KJ, Chae MJ, Lee HS, Hong HD, Park K (2010). Effects of Korean red ginseng on sexual arousal in menopausal women: placebo-controlled, double-blind crossover clinical study. Journal of Sexual Medicine. — PubMed PMID: 20141583
  7. Chen X (1996). Cardiovascular protection by ginsenosides and their nitric oxide releasing action. Clinical and Experimental Pharmacology and Physiology. — PubMed PMID: 8886498
  8. Murphy LL, Lee TJ (2002). Ginseng, sex behavior, and nitric oxide. Annals of the New York Academy of Sciences. — PubMed PMID: 12076988
  9. Salvati G et al. (1996). Effects of Panax Ginseng C.A. Meyer saponins on male fertility. Panminerva Medica. — PubMed PMID: 9063034
  10. Borrelli F et al. (2018). Herbal dietary supplements for erectile dysfunction: a systematic review and meta-analysis. Drugs. — PubMed PMID: 29633089
  11. Lee HW et al. (2021). Ginseng for erectile dysfunction. Cochrane Database of Systematic Reviews. — PubMed PMID: 33871063
  12. Lee YH et al. (2010). Interaction between warfarin and Korean red ginseng in patients with cardiac valve replacement. International Journal of Cardiology. — PubMed PMID: 19913311
  13. Lee SH et al. (2008). Interaction between warfarin and Panax ginseng in ischemic stroke patients. Journal of Alternative and Complementary Medicine. — PubMed PMID: 18637764
  14. Jiang X et al. (2004). Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. British Journal of Clinical Pharmacology. — PubMed PMID: 15089812

PubMed Topic Searches

  1. PubMed: KRG erectile dysfunction
  2. PubMed: Rg1 eNOS
  3. PubMed: Ginseng vs PDE5 inhibitors
  4. PubMed: KRG female sexual function
  5. PubMed: Ginseng male fertility

Back to Table of Contents

Connections

Back to Table of Contents